Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
News Archive
October 2021
September 2021
-
Pulse UpdateSep 28, 2021FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
-
Pulse UpdateSep 03, 2021Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients
-
Pulse UpdateSep 02, 2021Novartis receives FDA fast track designation for LNA043 in osteoarthritis of the knee
August 2021
-
Pulse UpdateAug 30, 2021Novartis sabatolimab receives orphan drug designation from the European Commission for myelodysplastic syndromes
-
Pulse UpdateAug 25, 2021FDA accelerates review of Novartis STAMP inhibitor asciminib (ABL001) for patients with chronic myeloid leukemia (CML)
-
Featured NewsAug 06, 2021Asia Pacific Patient Innovation Summit examines capability building gaps of Patient Organizations
